Skip to main content

Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7

View Digital Edition

Foreward - The Fifth Annual Payers’ Guide to New FDA Approvals

Introduction - New FDA Drug Approvals in 2013

Gary M. Owens, MD

FDA Approvals of Brand-Name Prescription Drugs in 2013

Specialty Drugs Top the Trends in the 2014 Pipeline

Dalia Buffery, MA, ABD

Abraxane (nab-Paclitaxel) Receives a New Indication for the Treatment of Patients with Metastatic Pancreatic Cancer

Lisa A. Raedler, PhD, RPh

Adempas (Riociguat): A Novel, First-in-Class Therapy Approved for the Treatment of 2 Types of Pulmonary Hypertension

Lisa A. Raedler, PhD, RPh

Amitiza (Lubiprostone): The First Oral Treatment Approved by the FDA for Opioid-Induced Constipation

Anoro Ellipta (Umeclidinium/Vilanterol): First Dual Long-Acting Inhaler for Long-Term Maintenance Treatment of COPD

Lisa A. Raedler, PhD, RPh

Botox (OnabotulinumtoxinA) Now FDA Approved for Overactive Bladder

Breo Ellipta (Fluticasone Furoate/Vilanterol): Fixed-Dose Combination Oral Inhaler Receives FDA Approval for Long-Term Maintenance Treatment of COPD

Page 1 of 4
Results 1 - 10 of 33